Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

This study is testing whether adding a new drug called iadademstat (an LSD1 inhibitor) to the standard combination of venetoclax and azacitidine can improve outcomes for older or less fit patients with newly diagnosed intermediate or high-risk AML (acute myeloid leukemia). **You may be eligible if...** - You are 18 or older and have been newly diagnosed with intermediate or high-risk AML (excluding APL) - You have not received prior AML treatment (except hydroxyurea) - You are physically able to swallow oral medications and weigh at least 50 kg - Your physical performance is adequate (ECOG 0-2) - Your liver, kidney, and heart function meet the required thresholds **You may NOT be eligible if...** - You have been previously treated for AML - You have APL (M3 type AML) - You have serious heart, liver, or kidney conditions beyond acceptable ranges - You are pregnant or breastfeeding - You have uncontrolled serious infection Talk to your doctor to see if this trial is right for you.